TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28347572
Drug: Paracetamol (1g,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (1g, six hourly)
Study: 28347572
Drug: Nefopam (20mg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam (20mg, six hourly)
Study: 20803609
Drug: Relaxation response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Relaxation response therapy (RRT)
Study: 17313507
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of malaria and multivitamin supplementation
Study: 11318884
Drug: Sumatriptan nasal
Normalized name: SUMAtriptan nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan nasal spray, 20 mg
Study: 9848497
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein as half of the daily protein intake
Study: 22999399
Drug: 0.25mg.kg(‐1) of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25mg.kg(‐1) of S(+)‐ ketamine diluted in 20mL of saline solution 0.9% (Group A)
Study: 22999399
Drug: 0.5mg.kg(‐1) of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5mg.kg(‐1) of S(+)‐ ketamine diluted in 20mL of saline solution 0.9% (Group B)
Study: 9343285
Drug: Calcium Supplement
Normalized name: Calcium supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium Supplement
Study: 7872895
Drug: Cisplatin administered
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin administered 72 hr after the initiation of continuous 5-FU infusion (Group B)
Study: 3146539
Drug: Enprostil 70
Normalized name: enprostil
DrugBank: Enprostil (DB13824)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enprostil 70 mcg/d
Study: 19040645
Drug: Insulin glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin glulisine at breakfast
Study: 19040645
Drug: Insulin glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin glulisine at main mealtime
Study: 15129595
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine premedication (5 micrograms/kg 1 hr before anesthesia)
Study: 10423465
Drug: Oral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral therapy with ciprofloxacin (750 mg twice daily) plus amoxicillin‐clavulanate (625 mg three times daily)
Study: 10423465
Drug: Intravenous therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous therapy with ceftriaxone plus amikacin
Study: 8523657
Drug: Placebo (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intravenous NaCl 0.9%)
Study: 26349479
Drug: Local intra-arterial
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Local intra-arterial fibrinolysis (LIF) and Conservative standard treatment (CST)
Study: 19335503
Drug: At-home preparation
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: At-home preparation group (experimental group)
Study: 15516638
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (14 days of ferrous sulfate and an antimalarial)
Study: 15516638
Drug: Extended treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended treatment (three months of ferrous sulfate and three antimalarial treatments)
Study: 8182625
Drug: Etodolac coadministered
Normalized name: Etodolac
DrugBank: Etodolac (DB00749)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etodolac coadministered with MTX (10 mg)
Study: 8182625
Drug: MTX (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX (10 mg) without etodolac
Study: 23622565
Drug: Intravenous antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotics + oral steroids (Group 2)
Study: 23622565
Drug: Intravenous antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotics (Group 1)
Study: 18467719
Drug: Lapatinib 1,250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib 1,250 mg daily (in patients with EGFR-overexpressed tumors)
Study: 12583871
Drug: buspirone (5HT1A
Approvals — FDA: no, EMA: no, PMDA: no
Description: buspirone (5HT1A receptor agonist)
Study: 8772550
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered at similar intervals as Acipimox)
Study: 4091874
Drug: Tramadol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (50 mg capsules, daily dosage limited to 400 mg for 3 weeks)
Study: 29571962
Drug: Heparin-free TPE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-free TPE
Study: 29571962
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin TPE
Study: 12441015
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with nitrendipine, enalapril, hydrochlorothiazide, or both to control systolic blood pressure to <150 mmHg
Study: 2178396
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg twice daily until complete ulcer healing (Group A)
Study: 2178396
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg until complete relief of pain (Group B)
Study: 2178396
Drug: Ranitidine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine treatment (both groups)
Study: 29936455
Drug: Oligomeric proanthocyanidin
Normalized name: grape seed proanthocyanidins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oligomeric proanthocyanidin (OPC) 150 mg/day for 8 weeks
Study: 25260636
Drug: nNOS inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: nNOS inhibitor (5 mm N-propyl-l-arginine)
Study: 25260636
Drug: eNOS inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: eNOS inhibitor (10 mm N(5)-(1-iminoethyl)-l-ornithine dihydrochloride)
Study: 25260636
Drug: Non-selective NOS
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-selective NOS inhibitor (20 mm Nω-nitro-l-arginine methyl ester hydrochloride)
Study: 10589633
Drug: Forearm IVRA
Normalized name: Ivra
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forearm IVRA (0.4 mL/kg, max 25 mL)
Study: 10589633
Drug: Conventional IVRA
Normalized name: Ivra
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional IVRA (0.6 mL/kg, max 45 mL)
Study: 1927586
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of pseudoephedrine four times a day for 3 days
Study: 1927586
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules four times a day for 3 days
Study: 6349925
Drug: Three-phasic oral
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-phasic oral contraceptive Trionetta (30/40/30 micrograms ethinyl oestradiol + 50/75/125 micrograms levonorgestrel)
Study: 27210034
Drug: Single implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single implants placed in healed ridges
Study: 21157444
Drug: Rifaximin (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin (1200 mg/day for 8 weeks)
Study: 15383479
Drug: Subcutaneous low
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous low molecular weight heparin (LMWH) or IV unfractionated heparin (UFH) for short-term treatment of DVT.
Study: 15383479
Drug: Anticoagulants while
Normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulants while awaiting diagnostic tests for patients with high clinical suspicion of DVT.
Study: 15383479
Drug: Initial treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment with LMWH or UFH for at least 5 days for acute DVT.
Study: 15383479
Drug: Initiation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initiation of vitamin K antagonist (VKA) together with LMWH or UFH on the first treatment day.
Study: 15383479
Drug: Long-term treatment
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term treatment with VKA for 3 months for first episode of DVT secondary to a transient risk factor.
Study: 15383479
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with VKA for at least 6 to 12 months for first episode of idiopathic DVT.
Study: 8866633
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg quinine
Study: 2106837
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further therapy
Study: 22748821
Drug: Linagliptin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin (5 mg)
Study: 18833113
Drug: Xydifonum administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xydifonum administered via various modes (electrophoretic, peroral, ointment) with heparin and photopheresis using photomatrix LED equipment.
Study: 6347277
Drug: Tamoxifen (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (30 mg daily for 1 year)
Study: 29722045
Drug: Body Project
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body Project intervention (n = 17) - participants tracked daily diet and activity, attended four weekly group-based sessions
Study: 29722045
Drug: Standard group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard group (n = 15) - directed to track diet and activity level daily
Study: 26035740
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules and placebo mouth rinse (PLACEBO)
Study: 21689411
Drug: Donepezil 23
Normalized name: donepezil 23 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 23 mg/day
Study: 19570066
Drug: Draw-the-Family Test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Draw-the-Family Test (DFT) administered to patients with benign anorectal disease
Study: 19570066
Drug: Draw-the-Family Test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Draw-the-Family Test (DFT) administered to patients with organic disease
Study: 19570066
Drug: Draw-the-Family Test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Draw-the-Family Test (DFT) administered to patients who failed treatment
Study: 19570066
Drug: Draw-the-Family Test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Draw-the-Family Test (DFT) administered to healthy control subjects
Study: 17095947
Drug: Sodium-selenite (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium-selenite (1000 microg as a 30-min bolus injection, followed by 14 daily continuous infusions of 1000 microg intravenously)
Study: 14985680
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (4 g/day, 56% DHA and 28% EPA)
Study: 31243641
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two tablets/day for 6 months)
Study: 20203367
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (200 mg p/o from the preoperative day till the 7th postoperative day)
Study: 7144761
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no vitamin E treatment)
Study: 12189059
Drug: Proven effective
Normalized name: Propoven
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proven effective treatment
Study: 365795
Drug: Viminol (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viminol (70 mg) combined with chlordiazepoxide (10 mg)
Study: 365795
Drug: Chlordiazepoxide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlordiazepoxide (10 mg)
Study: 30213641
Drug: Non-selective information
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-selective information (complete/unbiased) and absolute risk formats (e.g., 0.01 per 100)
Study: 24571621
Drug: Modified assertive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified assertive intervention based on the international assertive community treatment model
Study: 22207490
Drug: Fentanyl (FE,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (FE, 1-2 μg/kg)
Study: 20100959
Drug: Control empty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control empty vectors plus saline injections
Study: 16279894
Drug: Steroid injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid injection (0.5 cc/quadrant triamcinolone 40 mg/cc)
Study: 2050230
Drug: Topical retinoic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical retinoic acid 0.01%, 0.025%, or 0.05% applied for 10 days
Study: 2050230
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of triamcinolone acetonide 0.1% and retinoic acid 0.025%
Study: 6342544
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of salbutamol (inhalational powder and tablets)
Study: 6342544
Drug: Tablet treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet treatment of salbutamol
Study: 6342544
Drug: Inhalational powder
Normalized name: Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalational powder treatment of salbutamol
Study: 6342544
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of salbutamol
Study: 6342544
Drug: Combined or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined or tablet treatment of salbutamol
Study: 22234381
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg of risperidone
Study: 17413949
Drug: Eyelid hygiene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eyelid hygiene once daily
Study: 30180918
Drug: Oxytocin (36
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin (36 IU BID, supervised administration 45 min prior to CBSST sessions)
Study: 24444140
Drug: Brief psychodynamic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief psychodynamic psychotherapy (eight sessions administered at two-week intervals)
Study: 24444140
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (clinical interview, neurological examination, counselling, symptomatic therapy)
Study: 16331769
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac diethylamine gel, 1.16%, 4 g applied qid for 3 weeks
Study: 11964340
Drug: Training package
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training package of four half days on brief cognitive behaviour therapy
Study: 2499178
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy plus intradermal immunization with viral oncolysate (VO)
Study: 1138642
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of low-dose heparin and hydrocortisone
Study: 7378674
Drug: Iotroxamide infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iotroxamide infusion at rates of 0.525 to 6.3 mg/kg/min
Study: 7378674
Drug: Iotroxamide infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iotroxamide infusion at an optimal rate of around 4 mg/kg/min
Study: 26269566
Drug: l-alanyl-l-glutamine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-alanyl-l-glutamine (8 g/d) and polyunsaturated fatty acid (6.5 g/d)
Study: 19856790
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of cetirizine hydrochloride
Study: 11154482
Drug: Topical pharyngeal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical pharyngeal anesthesia
Study: 9663180
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day oral fluconazole
Study: 3146891
Drug: L-5-hydroxytryptophan (L-5HTP)
Normalized name: L-5-HTP
DrugBank: Oxitriptan (DB02959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-5-hydroxytryptophan (L-5HTP)
Study: 24078554
Drug: Flurbiprofen axetil
Normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen axetil 1 mg·kg(‐1)
Study: 19673614
Drug: Rosiglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 4 mg twice daily for 4 days
Study: 29932413
Drug: 0.5-mg DuvieTM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5-mg DuvieTM tablets (test drug)
Study: 29932413
Drug: 0.5-mg DuvieTM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5-mg DuvieTM tablets (reference drug)
Study: 10619929
Drug: Duraflo II
Normalized name: Duraflor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duraflo II heparin-coated cardiopulmonary bypass circuits
Study: 1826237
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of unmodified insulin (10 U)
Study: 1826237
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of unmodified insulin (10 U)
Study: 7122669
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg valerian extract
Study: 2371367
Drug: Midazolam (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (5 mg)
Study: 24576515
Drug: Supplemental oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental oxygen 6 L/min delivered by Oxymask for 6 to 12 hours
Study: 22569622
Drug: ETT intracuff
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETT intracuff 2% lidocaine plus 8.4% sodium bicarbonate (L group)
Study: 20385439
Drug: Posterior maxilla
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posterior maxilla implants without sinus lift
Study: 19238877
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid supplementation (0.4 mg/day) starting at least one month before conception and continuing for the first quarter of pregnancy
Study: 1901808
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg ponalrestat
Study: 7179208
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of heparin (i.v.)
Study: 7179208
Drug: Subcutaneous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous heparin (s.c.)
Study: 24267731
Drug: Metformin 1000
Normalized name: metformin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1000 mg/day
Study: 26917112
Drug: DRV/r 800/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: DRV/r 800/100 mg once daily
Study: 21149923
Drug: LPV/r 800/200
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPV/r 800/200 mg total daily dose
Study: 12126926
Drug: Pentaspan (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentaspan (500 ml, infusion condition)
Study: 12126926
Drug: Placebo (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (60 ml saline, non-infusion condition)
Study: 3017596
Drug: Domperidone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (20 mg)
Study: 30672192
Drug: Conventional drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional drug therapy combined with acupuncture (Baihui, Sishencong, Neiguan, Hegu, Taixi), treatment given once daily, 6 times a week for 4 weeks.
Study: 30672192
Drug: Conventional drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional drug therapy only, treatment given once daily, 6 times a week for 4 weeks.
Study: 17920108
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy using cisplatin/cyclophosphamide or cisplatin/paclitaxel chemotherapy
Study: 27228432
Drug: SHAM treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHAM treatment, n=33
Study: 23131255
Drug: Low-dose linezolid
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose linezolid treatment for MDR-TB (16 weeks, daily dosage)
Study: 31829925
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of atorvastatin (20 mg)
Study: 31829925
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of atorvastatin (20 mg)
Study: 20678686
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of ortho-hydroxy-atorvastatin (20 mg)
Study: 20678686
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of ortho-hydroxy-atorvastatin (20 mg)
Study: 17660388
Drug: Systemic infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic infusion of L-NMMA (10 mg/kg)
Study: 15711037
Drug: Heparin-protamine (HP)
Normalized name: protamines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-protamine (HP) post-filter
Study: 15547086
Drug: DHEA 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA 200 mg/day
Study: 11254817
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate
Study: 23891440
Drug: High-protein diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein diet enriched with β-hydroxy-β-methylbutirate, calcium, and vitamin D administered during 30 days of hospitalization.
Study: 23891440
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet administered during 30 days of hospitalization.
Study: 12637119
Drug: Choline alfoscerate
Normalized name: Choline Alfoscerate
DrugBank: Choline alfoscerate (DB04660)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline alfoscerate (CA) 400 mg capsules, 3 times daily for 180 days